On July 4, 2023, the recombinant anti human IL-4Ra and IL-5 double antibody injection (RC1416 injection) independently developed by Nanjing RegeneCore Biotech Co.,Ltd(hereinafter referred to as RegeneCore) completed the administration of the first subject in CHINA-JAPAN FRIENDSHIP HOSPITAL, marking that the development of antibody drugs in RegeneCore has entered the clinical research stage. The purpose of this study was to evaluate the safety and tolerability in Chinese healthy subjects.

Rc1416 is the first bispecific antibody drug developed by RegeneCore based on nanobody. By blocking IL-4, IL-5 and IL-13 signaling pathways, it can be used for the treatment of diseases related to excessive activation of Th2 immune cell pathways.

REGENECORE is gradually practicing clinical demand and market-oriented technological innovation, and continues to move firmly on the road of "Make a better life with innovative medicines".

Figure 1: Schematic diagram of molecular mechanisms related to Th2 inflammation[1]

Reference:

[1]Gandhi NA, Bennett BL, Graham NM, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016 Jan;15(1):35-50. doi: 10.1038/nrd4624. Epub 2015 Oct 16. PMID: 26471366.Reference: